

FSD Pharma

08:50 22 Jun 2020

FSD Pharma says Phase 1 study finds micro-PEA "safe and well tolerated"

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) announced Monday that a Phase 1 study of ultramicro-nized palmitoylethanolamide (PEA), or FSD201, found the drug "to be safe and well tolerated."

The company noted that mild and self-limiting side effects were reported and were deemed unlikely to be related to the study of the anti-inflammatory drug.

In addition, there were no abnormal laboratory findings or ECGs observed during the study and no serious adverse events were reported. And no subjects withdrew due to an adverse event and all eligible subjects completed all doses.

READ: FSD Pharma wins FDA nod to design Phase 2a clinical trial of its lead candidate micro-PEA to treat coronavirus patients

CEO Dr Raza Bokhari said the company will submit the top-line results from the randomized, double-blind, placebo-controlled study for publication in a peer-reviewed journal and to launch a Phase 2a proof-of-concept trial of FSD201 for the treatment of COVID-19.

The company said that severe COVID-19 disease caused by the SARS-CoV-2 virus is characterized by an "over-exuberant inflammatory response" that may lead to a cytokine storm and ultimately death. FSD Pharma is focused on developing FSD-201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.

"The US Food and Drug Administration recently gave the company permission to submit an Investigational New Drug application for the use of FSD201 to treat COVID-19," Bokhari said in a statement.

"We contacted the FDA after becoming aware that Italian physicians and scientists were advocating for use of ultramicro-nized PEA for patients suffering from symptoms of COVID-19, based on the drug's mechanism of action as a potent and safe anti-inflammatory agent that reduces the production of pro-inflammatory cytokines and may help mitigate a cytokine storm."

The single-site study was conducted at the Alfred Hospital, part of the Alfred Health group of hospitals serving the state of Victoria in Australia and enrolled 48 healthy adult men and women.


The trial sequentially tested single ascending doses ranging from 600 milligrams (mg) to 2400 mg tablets and multiple ascending doses ranging from 600 mg to 1200 mg tablets administered twice daily for seven consecutive days. The single ascending dose subjects also were tested for food effect.

FSD Pharma said it is not making any express or implied claims that its product has the ability to eliminate, cure or contain COVID-19 (or the SARS-2 coronavirus) at this time.

Price: 3.55

Market Cap: \$52.27 m

1 Year Share Price Graph



September 2019 March 2020 September 2020

Share Information

Code: HUGE

Listing: CSE

52 week	High	Low
	20.1	3.35

Sector: Pharma & Biotech

Website: fsdpharma.com

Company Synopsis:

FSD Pharma Inc. is a publicly-traded holding company, since May 2018. FSD Pharma BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, ultramicro-nized-palmitoylethanolamide ("FSD201"), by down-regulating the cytokines to effectuate an anti-inflammatory response.

action@proactiveinvestors.com

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter [@PatrickMGraham](https://twitter.com/PatrickMGraham)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).